Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm

Haematologica. 2023 May 1;108(5):1423-1428. doi: 10.3324/haematol.2022.282019.

Authors

Naseema Gangat¹, Rimal Ilyas², Kristen McCullough², Kebede H Begna², Aref Al-Kali², Mrinal M Patnaik², Mark R Litzow², William J Hogan², Abhishek Mangaonkar², Hassan Alkhateeb², Mithun V Shah², Michelle A Elliott², James M Foran³, Talha Badar³, Jeanne M Palmer⁴, Curtis A Hanson⁵, Animesh Pardanani², Ayalew Tefferi⁶

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN. gangat.naseema@mayo.edu.
² Division of Hematology, Mayo Clinic, Rochester, MN.
³ Division of Hematology, Mayo Clinic, Jacksonville FL.
⁴ Division of Hematology, Mayo Clinic, Scottsdale, AZ.
⁵ Division of Hematopathology, Mayo Clinic, Rochester, MN.
⁶ Division of Hematology, Mayo Clinic, Rochester, MN. tefferi.ayalew@mayo.edu.

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute*
Myeloproliferative Disorders* / drug therapy
Neoplasms*
Sulfonamides / therapeutic use

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides